WYETH PHARMACEUTICALS INITIATES PHASE II AND PAYS ABLYNX ANOTHER
MILESTONE IN THE TNF-alpha NANOBODY
(Thomson Reuters ONE) - Ghent, Belgium, 30 September 2009 - Ablynx [Euronext Brussels: ABLX],today announced that it has reached a second milestone under theterms of its collaboration with Wyeth Pharmaceuticals, a division ofWyeth. A milestone payment of $4 million has been triggered by theinitiation by Wyeth of a first Phase II multiple dose study inpatients with rheumatoid arthritis (RA) for a Nanobody® targetingtumour necrosis factor alpha (TNF-alpha).Wyeth entered into a Phase I study in healthy volunteers in December2008 in the USA and Japan. Based on a successful conclusion of thatstudy, where the Nanobody® was safe and well tolerated, Wyeth hastoday initiated a multiple dose Phase II study in RA patients. Ablynxentered into an exclusive research collaboration and licenseagreement with Wyeth Pharmaceuticals in November 2006, a dealpotentially worth $212.5 million for the successful development andcommercialisation of multiple products. In addition, Ablynx iseligible to receive royalties on product sales. Wyeth has exclusiverights to develop and commercialise anti-TNF-alpha Nanobodies®developed under the collaboration. TNF-alpha is a key drug target incombating inflammation related disorders such as rheumatoidarthritis, Crohn's disease, psoriatic arthritis and ankylosingspondylitis.Dr Edwin Moses, CEO and Chairman of Ablynx commented: "After asuccessful Phase I study in healthy volunteers in the USA and Japan,we are delighted that Wyeth has progressed the TNF-alpha programmeinto a Phase II study in patients with RA. Therapeutics targetingTNF-alpha generated $16.8 billion in sales in 2008, and WyethPharmaceuticals is well positioned with its Enbrel franchise toprogress this Nanobody® programme towards the market and createanother great success." -ends-For more information, please contact:For international media enquiries:College Hill Life SciencesSue Charles, Justine Lamond,Dr John McIntyret: +44 (0)20 7866 7857e: ablynx(at)collegehill.comAblynx:Dr Edwin MosesChairman and CEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193e: edwin.moses(at)ablynx.comEva-Lotta AllanChief Business Officert: +32 (0)9 262 00 75m: +32 (0)475 78 36 21 /+44 (0)7990 570 900e: eva-lotta.allan(at)ablynx.comhttp://hugin.info/137912/R/1344997/322669.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 30.09.2009 - 18:00 Uhr
Sprache: Deutsch
News-ID 6443
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 279 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"WYETH PHARMACEUTICALS INITIATES PHASE II AND PAYS ABLYNX ANOTHER
MILESTONE IN THE TNF-alpha NANOBODY"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
